ALLMedicine™ Mycobacterium Kansasii Center
Research & Reviews 84 results
Antimicrobial Agents and Chemotherapy; Srivastava S, Boorgula GD et. al.
Mar 23rd, 2022 - There is limited high-quality evidence to guide the optimal treatment of Mycobacterium kansasii pulmonary disease. We retrospectively collected clinical data from 33 patients with M. kansasii pulmonary disease to determine the time-to-sputum cultu...
Pathogens and Global Health; Akrami S, Dokht Khosravi A et. al.
Mar 10th, 2022 - There are limited studies on the antibiotic resistance patterns of slowly growing mycobacteria (SGM) species and their related gene mutations in Iran. This study aimed to elucidate the antibiotic susceptibility profiles and the mutations in some g...
The Lancet. Infectious Diseases; Lange C, Böttger EC et. al.
Jan 30th, 2022 - The 2020 clinical practice guideline for the treatment of non-tuberculous mycobacterial pulmonary disease (NTM-PD) by the American Thoracic Society, European Respiratory Society, European Society of Clinical Microbiology and Infectious Diseases, a...
Journal of Global Antimicrobial Resistance; Srivastava S, Pasipanodya JG et. al.
Dec 22nd, 2021 - The aim of this study was to determine and compare the efficacy of drugs to treat Mycobacterium kansasii (Mkn) pulmonary disease by performing minimum inhibitory concentration (MIC) determination and time-kill studies. We determined the MICs to 13...
BMJ Case Reports; Flowers RC, Ocampo J et. al.
Dec 2nd, 2021 - A gentleman in his 60s with end-stage kidney disease status post kidney transplantation on prednisone and tacrolimus presented with generalised weakness for 7 days, associated with altered mental status. Investigations revealed pancytopenia, acute...
Guidelines 2 results
Clinical Infectious Diseases : an Official Publication Of... Daley CL, Iaccarino JM et. al.
Aug 17th, 2020 - Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (wit...
The European Respiratory Journal; Daley CL, Iaccarino JM et. al.
Jul 9th, 2020 - Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (wit...
News 3 results
Sep 19th, 2019 - In addition to this change in antibiotic coverage, the patient’s medical oncologist tapered the patient’s immunosuppression considerably. The patient subsequently completed 12 months of therapy with clarithromycin, moxifloxacin, and rifabutin star.
Heidi Splete, MDedge News
May 15th, 2017 - Nontuberculous mycobacteria accounts for an increasing percentage of pulmonary disease, and nonsurgical treatment alone has not shown effectiveness, according to data from a meta-analysis of 24 studies and 1,224 patients. The study results were pu.
Jessica Sprague, MD, MS, Matthew Leibowitz, MD et. al.
Jul 7th, 2015 - To the Editor: A 68-year-old man with a history of myelodysplastic syndrome and recurrent Sweet syndrome presented with left leg lesions of 3 months’ duration. The lesions originated as a solitary nodule on the left calf and subsequently developed.